OUR STORY
The African continent which is home for more than 1.3 billion people imports 80 percent of its biopharmaceutical and medical consumables. However, most African countries do not have a strong regulatory system and often times lack resources to perform quality control on imported biopharmaceutical and medical products. These problems have led to a huge spread of counterfeit drugs throughout the continent. According to the World Health Organization more than 42 percent of counterfeit drugs sold globally between 2013 and 2017 were in Africa, accounting for nearly $80 billion.
Since 2013, Afeli Pharmaceuticals has been working diligently to address the crucial needs for high-quality healthcare products throughout the African continent. Our mission is to offer solutions that address the unmet needs of high-quality biopharmaceutical products in Africa from strategy to implementation.
- In 2014, we seek to reduce the risk of serious birth defects, infant and maternal mortality in Africa through the production and distribution of a U.S.-made prenatal multivitamin complex to pregnant and breastfeeding women in Ivory Coast and Zambia.
- In 2016, we launched our U.S.-made joint pain supplement, a clinically proven formula which help promote joint comfort.
- We have also worked with rural clinics, health sector government officials, hospitals, pharmacies, regulatory affairs officials, non-government organization throughout Africa to bring strategic solutions to their healthcare needs.
- We are planning for the construction of a 50,000 sqft distribution and fulfillment center in the state of South Carolina which will be exclusively dedicated to the export of biopharmaceuticals and medical consumables to Africa.
WHO ARE WE?
Serge Afeli, PhD, MSHA | Founder and CEO
Dr. Afeli was born in Cote d’Ivoire (Ivory Coast) and raised in a family of six children in the city of Abidjan before immigrating to the United States to attend college and complete his higher education degrees. Dr. Afeli holds a bachelor’s degree in physical sciences from Kansas State University, a PhD degree in pharmaceutical sciences from the University of South Carolina College of Pharmacy, and a master’s degree in Healthcare Administration from the University of Alabama at Birmingham.
Dr. Afeli is currently a tenured Associate Professor of Pharmacology and Director of Pharmacy Innovation and Entrepreneurship at Presbyterian College School of Pharmacy. He is the author of more than two dozen peer-reviewed research articles in the field of urology, bladder cancer, pharmacy education and entrepreneurship. Dr. Afeli has more than 12 years of experience in pharmacological research and his scientific publications have provided significant insight in the pathophysiology of overactive bladder, a disease that affect ~33 million people in the U.S. alone.
Serge Afeli, PhD, MSHA
BOARD OF ADVISORS
Latif Oduola-Owoo, Esq
Latif Oduola-Owoo, Esq
Latif Oduola-Owoo, Esq
Legal and Strategy Advisor
Partner at Arrington-Owoo Law Firm
Brian Boughner
Latif Oduola-Owoo, Esq
Latif Oduola-Owoo, Esq
Financial Strategy Advisor
Principal at Parallel Financials LLC
Fiston Vuvu, PharmD, MSc
Fiston Vuvu, PharmD, MSc
Fiston Vuvu, PharmD, MSc
Pharmaceutical Strategy Advisor
Global Health Economics and Outcomes Research at Pfizer
Pete Oliver
Fiston Vuvu, PharmD, MSc
Fiston Vuvu, PharmD, MSc
Business Strategy Advisor
CEO of Oliver Trading Inc.,
market presence
United States
Côte d'Ivoire (Ivory Coast)
Côte d'Ivoire (Ivory Coast)
Côte d'Ivoire (Ivory Coast)
Côte d'Ivoire (Ivory Coast)
Côte d'Ivoire (Ivory Coast)